Melanotan II
Also known as: MT-II, MT2
limited human dataNot FDA approvedResearch only
Published Dose Range
Low250 mcg/dose
Typical500-1000 mcg during loading, 1000 mcg/week maintenance
High1000 mcg/dose
Non-selective melanocortin receptor agonist. Research chemical — not approved for human use. Loading phase: low daily dose with gradual increase to assess tolerance.
Published Cycle Range
Short4 wks
Typical8 wks
Long12 wks
Cycle off after pigmentation is achieved. Repeat use has been associated with changes in existing moles.
Off-cycle: 4 weeks
Administration
Routessubcutaneous
FrequencyDaily during loading, 1-2x/week maintenance
Preferred timingEvening (side effects less disruptive during sleep)
Nausea and flushing are most noticeable in the 1-2 hours post-dose.
Safety Profile
Contraindications
- • History of melanoma or atypical nevi
- • Cardiovascular disease
- • Uncontrolled hypertension
Common side effects
- • Nausea (very common)
- • Flushing
- • Decreased appetite
- • Spontaneous erections
- • Focal hyperpigmentation
- • Darkening of existing moles
Serious risks
- • Reports of new melanocytic lesions and changes in existing moles
- • Not approved for human use
- • Quality and purity concerns with grey-market product
Requires monitoring
- • Full skin exam before and during use
Pregnancy / breastfeeding
Contraindicated
Sex-Specific Notes
Male
Spontaneous erections during loading phase are common
Common Misconceptions
- Not the same as Melanotan I (afamelanotide, Scenesse) — MT-II is non-selective and has more side effects
Next Steps
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.